Global Edaravone Market Size By Type (Oral Edaravone, Injection Edaravone), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Edaravone Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.5 billion by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. The market is primarily driven by the increasing prevalence of neurodegenerative diseases, growing geriatric population, and the rising adoption of edaravone for treating Amyotrophic Lateral Sclerosis (ALS) and ischemic stroke. Additionally, advancements in drug formulation and approvals in emerging markets are expected to accelerate market expansion.

Drivers

Rising Prevalence of Neurodegenerative Disorders

The increasing incidence of neurological conditions such as ALS, Alzheimer's, and Parkinson's disease is one of the key factors driving the edaravone market. Edaravone’s proven efficacy in reducing oxidative stress and delaying disease progression has led to higher adoption rates among healthcare providers.

Aging Population and Increasing Stroke Cases

The global aging population is a significant contributor to the rising cases of stroke and neurodegenerative disorders, creating a larger patient pool for edaravone treatments. With the elderly population expected to double by 2050, the demand for neuroprotective drugs like edaravone is set to rise substantially.

Expanding Regulatory Approvals

Several regulatory bodies, including the U.S. FDA, European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), have approved edaravone for ALS treatment. The expansion of approvals in Asia-Pacific and Latin America is expected to boost market growth further.

Restraints

High Cost of Treatment

Edaravone therapy is costly, particularly in high-income countries, which limits accessibility for a significant portion of the patient population. The high cost of intravenous formulations and ongoing therapy expenses can hinder widespread adoption.

Limited Awareness and Availability in Developing Regions

Despite its effectiveness, edaravone is not yet widely available in several low- and middle-income countries due to regulatory challenges and lack of awareness among healthcare professionals and patients.

Opportunity

Development of Oral Formulations

Pharmaceutical companies are focusing on the development of oral edaravone formulations to enhance patient compliance and reduce the cost burden associated with intravenous administration. The introduction of these formulations is expected to significantly expand the market.

Expansion in Emerging Markets

With the increasing burden of stroke and ALS cases in emerging economies, key market players are exploring opportunities for expansion in regions such as Asia-Pacific, Latin America, and the Middle East & Africa. Increased healthcare investments and improving access to neurological treatments will drive market growth in these regions.

Market by System Type Insights

Based on formulation type, the intravenous edaravone segment dominated the market in 2023 due to its proven efficacy and established presence in hospitals and clinics. However, the oral edaravone segment is expected to witness the highest growth rate during the forecast period, driven by ongoing research, patient preference, and ease of administration.

Market by End-use Insights

By end-use, the hospital segment accounted for the largest market share in 2023, as hospitals are the primary centers for neurodegenerative disease treatment. However, the home healthcare segment is anticipated to witness robust growth due to increasing adoption of oral edaravone formulations and advancements in home-based healthcare services.

Market by Regional Insights

North America dominated the market in 2023, holding the largest share due to high healthcare expenditure, regulatory approvals, and well-established neurological treatment infrastructure.

Europe is expected to remain a key market, driven by rising awareness and adoption of edaravone in ALS and stroke management.

Asia-Pacific is projected to experience the highest CAGR during the forecast period, fueled by increasing cases of neurological disorders, government support for drug approvals, and growing healthcare investments.

Latin America and the Middle East & Africa are emerging markets with significant growth potential as access to neuroprotective drugs improves.

Competitive Scenario

Leading players in the global edaravone market include:

Mitsubishi Tanabe Pharma Corporation

Sun Pharmaceutical Industries Ltd.

Lupin Pharmaceuticals, Inc.

Cipla Inc.

Teva Pharmaceuticals Industries Ltd.

Viatris Inc.

Apotex Inc.

Biogen Inc.

Pfizer Inc.

Takeda Pharmaceutical Company Limited

These companies are focusing on expanding their edaravone portfolios through research, partnerships, and acquisitions.

Scope of Work – Global Edaravone Market

Report Metric Details

Market Size (2023) USD 1.2 billion

Projected Market Size (2031) USD 2.5 billion

CAGR (2023-2031) 9.6%

Key Segments by Formulation Intravenous, Oral

Key Segments by End-Use Hospitals, Home Healthcare

Leading Region North America

Key Players Mitsubishi Tanabe, Sun Pharma, Teva, Cipla, Biogen, Pfizer

Key Market Developments

2023: Mitsubishi Tanabe Pharma Corporation expanded its production capacity to meet the growing demand for edaravone formulations.

2023: Sun Pharmaceutical launched a generic version of edaravone for ALS treatment in the U.S. market.

2024: Teva Pharmaceuticals partnered with a biotech company to develop a novel oral edaravone formulation for improved patient compliance.

2025: Biogen announced clinical trials for edaravone combination therapy for enhanced neuroprotection in ALS patients.

FAQs

1. What is the current market size of the Global Edaravone Market?

The market was valued at USD 1.2 billion in 2023.

2. What is the major growth driver of the Global Edaravone Market?

The primary driver is the rising prevalence of neurodegenerative diseases, particularly ALS and ischemic stroke.

3. Which is the largest region during the forecast period in the Global Edaravone Market?

North America holds the largest market share due to regulatory approvals and high adoption rates.

4. Which segment accounted for the largest market share in the Global Edaravone Market?

The intravenous edaravone segment dominated in 2023, while the oral formulation segment is expected to grow significantly.

5. Who are the key market players in the Global Edaravone Market?

Major players include Mitsubishi Tanabe Pharma, Sun Pharmaceutical, Teva Pharmaceuticals, Biogen, Pfizer, and Cipla.

This report provides a comprehensive analysis of the Global Edaravone Market, ensuring accuracy, clarity, and valuable insights for industry stakeholders.